Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
Microb Pathog ; 174: 105923, 2023 Jan.
Article in English | MEDLINE | ID: covidwho-2290808

ABSTRACT

Antibiotic resistance has become an indispensably alarming menace to the global community. The primary factors are overuse and abuse of antibiotics, lack of novel medicines under development, the health care industry's focus on profit, and the absence of diagnostic testing prior to the prescription of antibiotics. Additionally, over the past few decades, the main factors contributing to the global spread of antibiotic resistance have been the overuse of antibiotics in livestock and other animals, drug efficacy, development of fewer new vaccines, environmental toxicity, transmission through travel, and lack of funding for healthcare research and development. These factors have accelerated resistance in microorganisms through structural and functional modifications in bacteria such as reduced drug permeability, increased efflux pumps, enzymatic antibiotic modification, and change in drug target, intracellular infection, and biofilm creation. There has been an increase in resistance during the pandemic and among cancer patients due to improper prescriptions. A number of modern therapeutic alternatives have been developed to curb widespread antibiotic resistance such as nanoparticle, bacteriophage, and antimicrobial biochemical approaches. It is high time to explore new alternatives to curtail enormous increase in resistant pathogens which could be an incurable global confrontation. This review highlights the complete insight on the global drivers of resistance along with the modes of action and impacts, finally discussing the latest therapeutic alternatives.


Subject(s)
Bacteria , Pandemics , Animals , Drug Resistance, Microbial , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Travel
2.
Microb Pathog ; 179: 106088, 2023 Jun.
Article in English | MEDLINE | ID: covidwho-2248536

ABSTRACT

Significant efforts and initiatives were already made in the health care systems, however in the last few years; our world is facing emergences of viral infections which potentially leading to considerable challenges in terms of higher morbidity, mortality, increased and considerable financial loads on the affected populations. Over ten major epidemics or pandemics have been recorded in the twenty-first century, the ongoing coronavirus pandemic being one of them. Viruses being distinct obligate pathogens largely dependent on living beings are considered as one of the prominent causes of death globally. Although effective vaccines and antivirals have led to the eradication of imperative viral pathogens, the emergences of new viral infections as well as novel drug-resistant strains have necessitated the implementation of ingenious and efficient therapeutic approaches to treat viral outbreaks in the future. Nature being a constant source of tremendous therapeutical resources has inspired us to develop multi-target antiviral drugs, overcoming the challenges and limitations faced by pharmaceutical industry. Recent breakthroughs in the understanding of the cellular and molecular mechanisms of viral reproduction have laid the groundwork for potential treatment approaches including antiviral gene therapy relying on the application of precisely engineered nucleic acids for disabling pathogen replication. The development of RNA interference and advancements in genome manipulating tools have proven to be especially significant in this regard. In this review, we discussed mode of actions and pathophysiological events associated with the viral infections; followed by distributions, and advancement made towards the detection strategies for timely diagnosis. In the later section, current approaches to cope up the viral pathogens and their key limitations have also been elaborated. Lastly, we also explored some novel and potential targets to treat such infections, where attentions were made on next generation gene editing technologies.


Subject(s)
COVID-19 , Virus Diseases , Viruses , Humans , Virus Diseases/diagnosis , Virus Diseases/drug therapy , Antiviral Agents/therapeutic use , Viruses/genetics , Gene Editing
3.
Mol Biotechnol ; 2022 Apr 26.
Article in English | MEDLINE | ID: covidwho-2227193

ABSTRACT

Genome-editing technology has enabled scientists to make changes in model organisms' DNA at the genomic level to get biotechnologically important products from them. Most commonly employed technologies for this purpose are transcription activator like effector nucleases (TALENs), homing-endonucleases or meganucleases, zinc finger nucleases (ZFNs), and clustered regularly interspaced short palindromic repeats (CRISPR) associated protein 9 (Cas9). Among these tools, CRISPR/Cas9 is most preferred because it's easy to use, has a small mutation rate, has great effectiveness, low cost of development, and decreased rate of advancement. CRISPR/Cas9 has a lot of applications in plants, animals, humans, and microbes. It also has applications in many fields such as horticulture, cancer, food biotechnology, and targeted human genome treatments. CRISPR technology has shown great potential for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic to provide early and easy detection methods, possible treatment, and vaccine development. In the present review, genome-editing tools with their basic assembly and features have been discussed. Exceptional notice has been paid to CRISPR technology on basis of its structure and significant applications in humans, plants, animals, and microbes such as bacteria, viruses, and fungi. The review has also shed a little light on current CRISPR challenges and future perspectives.

4.
Library Philosophy and Practice ; : 1-11, 2022.
Article in English | ProQuest Central | ID: covidwho-2057412

ABSTRACT

Background: Medical librarians support curriculum and research by delivering appropriate and high-quality information and facilities to students and faculty members. COVID-19 pandemic disrupted physical teaching and learning worldwide endorsing virtual education which was supported by digital information resources. The purpose of this study was to evaluate the extent of utilization of physical and digital learning resources along with customer satisfaction in a health science library before and during the COVID-19 pandemic. Methods: An online self-administered questionnaire was administered using Microsoft Forms to students and faculty members. Data were analyzed using SPSS version 24. Qualitative variables were analyzed using mean and standard deviation. A Chi-square test was carried out to compare customers' satisfaction with the utilization of information resources before and during the pandemic. A p-value < 0.05 was considered to be statistically significant. Results: A total of 230 participants were included in the study. The library was visited by 18.7% and 26.1% of customers daily, and weekly respectively before the COVID-19 pandemic. However, none of them used the library daily during a pandemic, while digital library usage increased during this time. A significant reduction in the level of customers' satisfaction was observed with the physical library services in coronavirus outbreaks compared to satisfaction before the pandemic, p=0.028. Participants were satisfied with the utilization of digital library services during the pandemic compared to the prepandemic period, p= 0.024. Conclusion: The use of digital libraries surged during the pandemic resulting in a rapid adaptation of electronic books and journals. Librarians' have played a vital role in the current catastrophe by improving awareness of stakeholders regarding e-resources.

5.
Saudi J Biol Sci ; 29(6): 103274, 2022 Jun.
Article in English | MEDLINE | ID: covidwho-1757829

ABSTRACT

Recent worldwide outbreak of SARS-COV-2 pandemic has increased the thirst to discover and introduce antiviral drugs to combat it. The bioactive compounds from plant sources, especially terpenoid have protease inhibition activities so these may be much effective for the control of viral epidemics and may reduce the burden on health care system worldwide. Present study aims the use of terpenoid from selected plant source through bioinformatics tools for the inhibition of SARS-COV-2. This study is based on descriptive analysis. The Protein Data Bank and PubChem database were used for the analysis of SARS-COV-2 protease and plant source terpenoids. Molecular docking by using molegro virtual docker (MVD) software was carried out. The findings of study are based on the inhibitory actions of different plant sourced terpenoid against SARS-COV-2. As per the available resources and complementary analysis these phytochemicals have capacity to inhibit 3CLpro protease. The study reports that (3,3-dimethylally) isoflavone (Glycine max), licoleafol (Glycyrrhiza uralensis), myricitrin (Myrica cerifera), thymoquinone (Nigella sativa), bilobalide, ginkgolide A (Ginkgo biloba), Salvinorin A (Salvia divinorum), citral (Backhousia citriodora) and prephenazine (drug) showed high activity against SARS-COV-2 protease 3CLpro. The drug like and ADMET properties revealed that these compounds can safely be used as drugs. Cross structural analysis by using bioinformatics study concludes that these plant source terpenoid compounds can be effectively used as antiprotease drugs for SARS-COV-2 in future.

6.
J Virol Methods ; 300: 114375, 2022 Feb.
Article in English | MEDLINE | ID: covidwho-1654862

ABSTRACT

In late 2019, following the emergence of a ß-originated SARS-CoV-2, phylogenetic and evolutionary approaches have been demonstrated to strengthen the diagnostic and prophylactic stratagem of COVID-19 at an unprecedented level. Despite its clinical prominence, the SARS-CoV-2 gene set remains largely irrefutable by impeding the dissection of COVID-19 biology. However, many pieces of molecular and serological evidence have predicted that SARS-CoV-2 related viruses carry their roots from bats and pangolins of South East Asia. Analysis of viral genome predicts that point mutations at a rate of 10-4 nucleotides per base in the receptor-binding domain allow the emergence of new SARS-CoV-2 genomic variants at regular intervals. Research in the evolution of molecular pathways involved in emergence of pandemic is critical for the development of therapeutics and vaccines as well as the prevention of future zoonosis. By determining the phyletic lineages of the SARS-CoV-2 genomic variants and those of the conserved regions in the accessory and spike proteins of all the SARS-related coronaviruses, a universal vaccine against all human coronaviruses could be formulated which would revolutionize the field of medicine. This review highlighted the current development and future prospects of antiviral drugs, inhibitors, mesenchymal stem cells, passive immunization, targeted immune therapy and CRISPR-Cas-based prophylactic and therapeutic strategies against SARS-CoV-2. However, further investigations on Covid-19 pathogenesis is required for the successful fabrication of successful antivirals.


Subject(s)
COVID-19 , SARS-CoV-2 , Antiviral Agents , Humans , Pandemics , Phylogeny
7.
Library Philosophy and Practice ; : 1-10, 2020.
Article in English | ProQuest Central | ID: covidwho-948358

ABSTRACT

The parent study was conducted with an aim to determine the various bibliometric characteristics of the documents published in Journal of the Association for Information Science and Technology (JASIST) for 2014 to 2019. A retrospective study method was used and the data of JASIST were retrieved from Web of Science - Clarivate Analytics database. A total of 1,196 documents were found, contributed by the authors of 62 countries with average of 199 documents per annum. These documents received 11,941 citations with an average of 9.98 citations per documents. More than half of research were contributed by two countries, and amongst the top-10 most contributing organizations, six belonged to one country. The share of Asian countries has been recorded very low. JASIST has been providing excellent platform for dissemination of innovative ideas in the field of library and information Science since 1950.

8.
Drug Metab Rev ; 52(3): 408-424, 2020 08.
Article in English | MEDLINE | ID: covidwho-602031

ABSTRACT

Despite to outbreaks of highly pathogenic beta and alpha coronaviruses including severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and human coronavirus, the newly emerged 2019 coronavirus (COVID-19) is considered as a lethal zoonotic virus due to its deadly respiratory syndrome and high mortality rate among the human. Globally, more than 3,517,345 cases have been confirmed with 243,401 deaths due to Acute Respiratory Distress Syndrome (ARDS) caused by COVID-19. The antiviral drug discovery activity is required to control the persistence of COVID-19 circulation and the potential of the future emergence of coronavirus. However, the present review aims to highlight the important antiviral approaches, including interferons, ribavirin, mycophenolic acids, ritonavir, lopinavir, inhibitors, and monoclonal antibodies (mAbs) to provoke the nonstructural proteins and deactivate the structural and essential host elements of the virus to control and treat the infection of COVID-19 by inhibiting the viral entry, viral RNA replication and suppressing the viral protein expression. Moreover, the present review investigates the epidemiology, diagnosis, structure, and replication of COVID-19 for better understanding. It is recommended that these proteases, inhibitors, and antibodies could be a good therapeutic option in drug discovery to control the newly emerged coronavirus.HighlightsCOVID-19 has more than 79.5% identical sequence to SARS-CoV and a 96% identical sequence of the whole genome of bat coronaviruses.Acute respiratory distress syndrome (ARDS), renal failure, and septic shock are the possible clinical symptoms associated with COVID-19.Different antivirals, including interferons, ribavirin, lopinavir, and monoclonal antibodies (mAbs) could be the potent therapeutic agents against COVID-19.The initial clinical trials on hydroquinone in combination with azithromycin showed an admirable result in the reduction of COVID-19.The overexpression of inflammation response, cytokine dysregulation, and induction of apoptosis could be an well-organized factors to reduce the pathogenicity of COVID-19.


Subject(s)
Antiviral Agents/therapeutic use , Betacoronavirus , Coronavirus Infections/drug therapy , Drug Discovery , Pneumonia, Viral/drug therapy , Antibodies, Monoclonal/therapeutic use , Betacoronavirus/chemistry , Betacoronavirus/genetics , Betacoronavirus/physiology , COVID-19 , Coronavirus Infections/complications , Coronavirus Infections/epidemiology , Humans , Pandemics , Pneumonia, Viral/complications , Pneumonia, Viral/epidemiology , SARS-CoV-2 , Serine Endopeptidases/physiology , Serine Proteinase Inhibitors/therapeutic use , Virus Replication , COVID-19 Drug Treatment
SELECTION OF CITATIONS
SEARCH DETAIL